Diabetes therapies in hemodialysis patients: Dipeptidase-4 inhibitors

Table 3 Efficacies of dipeptidase-4 inhibitor monotherapies

Ref.	Studyduration (mo)	n	DPP-4 inhibitor	Treatment dose (mg)	Parameter(%)	Pre-treatment	Post-treatment	Efficacy
Arjona Ferreira et al[9]	12	64	Sitagliptin	25	HbA1c	7.9	7.2	-0.7
					GA	Unknown	Unknown	Unknown
Ito et al[10]	6	5	Vildagliptin	50	HbA1c	6.0	5.5	-0.5
					GA	21.8	19.7	-2.1
Kume et al[11]	6	26	Vildagliptin	50	HbA1c	Unknown	Unknown	Unknown
					GA	23.8	21.2	-2.6
Ito et al[12]	6	9	Vildagliptin	50 or 100	HbA1c	6.7	6.0	-0.7
					GA	24.7	20.1	-4.6
Nakamura et al[13]	24	16	Alogliptin	6.25	HbA1c	7.1	5.8	-1.3
					GA	22.5	19.6	-2.9
Nakamura et al[14]	6	21	Linagliptin	5	HbA1c	Unknown	Unknown	Unknown
					GA	21.3	18.0	-2.3
Otsuki et al[15]	6	14	Teneligliptin	20	HbA1c	6.4	Unknown	-0.3 to -0.8
	7				GA	21.1	Unknown	-1.7 to -2.3

HbA1c: Hemoglobin A1c; GA: Glycated albumin.